IDORSIA N chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.27
Dividend & YieldN/Afr (N/A)
Beta 0.65
Market capitalization 2.69B
Operating cash flow -835.94M
ESG Scores unknown

Company description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio6.52
Working Capital-0.7
Return On Equity-6.09
Debt To Equity10.49
Fixed Asset Ratio0
Fixed Interest Cover-22.92

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 2.42M 417k 599k 15.04M
Total Cashflows From Investing Activities 31.19M -74.81M -607.13M -53.26M
Net Borrowings 198.31M 594.56M 594.56M 594.56M
Total Cash From Financing Activities 497.76M 1.33M 850.08M 604.15M
Change To Operating Activities 11.7M 13.1M 32.19M -9.61M
Issuance Of Stock 299.45M 1.33M 850.08M 10M
Net Income -386.39M -493.61M -444.79M -634.6M
Change In Cash 176.1M -535.55M -122.2M -39.46M
Effect Of Exchange Rate -35k -34k -476k -452k
Total Cash From Operating Activities -352.82M -462.04M -364.67M -589.89M
Depreciation 19.56M 18.42M 17.73M 17.56M
Change To Account Receivables -126k -7.29M 2.73M -6.27M
Other Cashflows From Financing Activities -1k -1k -1k -418k
Change To Netincome -7.84M -2.51M 17.33M 6.82M
Capital Expenditures -11.62M -18.8M -9.27M -25.53M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -387.82M -485.2M -449.28M -634.8M
Net Income -386.39M -493.61M -444.79M -634.6M
Selling General Administrative 58.94M 65.14M 97.17M 230.17M
Gross Profit -309.46M -414.71M -309.32M -378.86M
Ebit -369.38M -481.12M -407.68M -609.5M
Operating Income -369.38M -481.12M -407.68M -609.5M
Interest Expense -8.73M -9.86M -9.05M -26.59M
Income Tax Expense -314k 9.45M -4.16M -210k
Total Revenue 60.62M 23.82M 71.76M 35.35M
Cost Of Revenue 370.08M 438.53M 381.08M 414.21M
Total Other Income ExpenseNet -18.45M -4.08M -41.6M -25.3M
Net Income From Continuing Ops -387.51M -494.65M -445.12M -634.6M
Net Income Applicable To Common Shares -386.39M -493.61M -444.79M -634.6M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 749.14M 839.85M 849.88M 1.38B
Total Stockholder Equity 664.68M 172.44M 585.48M 104.2M
Other Current Liabilities 31.16M 19.09M 19.16M 16.65M
Total Assets 1.41B 1B 1.44B 1.48B
Common Stock 6.55M 6.56M 8.32M 8.85M
Other Current Assets 5.01M 8.69M 7.14M 13.01M
Retained Earnings -400.66M -894.27M -1.35B -1.98B
Treasury Stock -6.44M -23.53M -38.1M -22.8M
Cash 798.56M 263.01M 140.81M 101.35M
Total Current Liabilities 104.85M 110.88M 127.47M 165.14M
Other Stockholder Equity -6.44M -23.53M -38.1M -22.8M
Property, Plant, and Equipment 150.7M 206.73M 196.22M 223.44M
Total Current Assets 941.42M 775.4M 1.03B 1.08B
Net Tangible Assets 661.88M 170.75M 584.9M 98.07M
Net Receivables 2.11M 5.95M 4.57M 4.61M
Accounts Payable 7.13M 8.76M 11.12M 26.86M


Insider Transactions

Here are the insider transactions of stock shares related to IDORSIA N:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to IDORSIA N. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on IDORSIA N

Here is the result of two systematic investment strategies applied to IDORSIA N. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on IDORSIA N

The following chart shows the equity curve of the two systematic investment strategies applied to IDORSIA N:

IDORSIA N automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -18.05% on the backtest period.

Performance at glance

Performance

-18.05 %

Latent gain

-264.36 fr

Invested capital

1464.91 fr

Annualized return

-4.38 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on IDORSIA N

This is the result of two momentum investment strategies applied to IDORSIA N. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on IDORSIA N

The following chart shows all the entries opened by the momentum investment system on IDORSIA N:

IDORSIA N momentum entries
  • The first momentum investment strategy would give -18.45% of return on IDORSIA N. That represents -1061.11fr of latent gain with 5752.49fr of employed capital.
  • The second momentum investment strategy would give -22.13% of return on IDORSIA N. That represents -608.88fr of latent gain with 2751.4fr of employed capital.
Performance at glance (1Q Momentum)

Performance

-18.45 %

Latent gain

-1061.11 fr

Invested capital

5752.49 fr

Annualized return

-6.85 %
Performance at glance (2Q Momentum)

Performance

-22.13 %

Latent gain

-608.88 fr

Invested capital

2751.4 fr

Annualized return

-6.08 %

Momentum equity curve on IDORSIA N

The following chart shows the equity curve of the two momentum strategies applied to IDORSIA N:

IDORSIA N momentum equity

Note: the dividends potentially given by IDORSIA N are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IDORSIA N

The following chart shows the employed capital evolution of the two momentum strategies on IDORSIA N since the beginning:

IDORSIA N

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250fr, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000fr.


Buy the dip strategy result on IDORSIA N

Buy the dip entry openings on IDORSIA N

IDORSIA N

The performance achieved by the robo-advisor on IDORSIA N is -14.53%. That represents -109.86$ of latent gain with 756.31fr of employed capital. The following chart shows IDORSIA N stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of IDORSIA N, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-14.53 %

Latent gain

-109.86 fr

Invested capital

756.31 fr

Annualized return

-6.85 %

Equity curve of the strategy applied to IDORSIA N

The following chart shows the result of the investment strategy applied to IDORSIA N:

IDORSIA N

Note: the dividends potentially given by IDORSIA N are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on IDORSIA N

The following chart shows the employed capital evolution since the beginning of the investment strategy on IDORSIA N:

IDORSIA N

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on IDORSIA N

In this section, I will compare the three previous investment strategies applied to IDORSIA N.

Equity curve comparison on IDORSIA N

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

IDORSIA N investment strategy comparison

Employed capital comparison on IDORSIA N

IDORSIA N investment comparison

Performance comparison on IDORSIA N

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -18.05% -264.36fr 1464.91fr -4.38%
Momentum 1 quarter -18.45% -1061.11fr 5752.49fr -4.76%
Momentum 2 quarters -22.13% -608.88fr 2751.4fr -6.08%
Non-directional -14.53% -109.86fr 756.31fr -6.85%
Annualized return comparison

Automatic investment

-4.38 %

Momentum 1Q

-6.08 %

Momentum 2Q

-6.08 %

Non-directional

-6.85 %

Correlated stocks

Here are the most positively and negatively correlated stocks with IDORSIA N:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between IDORSIA N and the other stocks. There may be false positives or some missing correlated stocks. If the price of IDORSIA N does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name IDORSIA N
Country Switzerland
City Allschwil
Address Hegenheimermattweg 91
Phone 41 58 844 10 10
Website www.idorsia.com
FullTime employees
Industry Biotechnology
Sector Healthcare
Exchange XSWX
Ticker IDIA.XSWX
Market www.six-group.com

IDORSIA N ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown